H-Index
10
Scimago Lab
powered by Scopus
eISSN: 2325-4416
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
AmJCaseRep

Annals
ISI-Home

A Review of Clinical and Preclinical Studies on Therapeutic Strategies Using Interleukin-12 in Cancer Therapy and the Protective Role of Interleukin-12 in Hematological Recovery in Chemoradiotherapy

Ping Li, Hong Zhang, Lina Ji, Zhi Wang

Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland)

Med Sci Monit 2020; 26:e923855

DOI: 10.12659/MSM.923855

Available online: 2020-06-18

Published: 2020-08-19


ABSTRACT: Interleukin-12 (IL-12), a heterodimeric glycoprotein with alpha and ß subunits covalently bonded with a disulfide bond, is a potent anticancer agent. Its action is accomplished through a linkage of the adaptive and innate immune responses. IL-12 can promote the recovery of the hematopoietic system after cancer chemoradiotherapy by stimulating the physiological processes of stem cells, including cell proliferation and differentiation, reconstitution of hematopoietic function, and peripheral blood count recovery. We review therapeutic strategies using IL-12 in clinical studies, including single-agent and combination strategies in hematological tumors and solid tumors, and studies on the protective effects of IL-12 in chemoradiotherapy. This review highlights promising therapeutic strategies based on the anticancer role of IL-12 and the potential protective effects of IL-12 for cancer patients receiving chemoradiotherapy.

Keywords: Hematologic Neoplasms, Interleukin-12, Neoplasms, Second Primary



Back